Ruxolitinib – March 2026

Tablet 5 mg, Tablet 10 mg, Tablet 15 mg, Tablet 20 mg

  • Brand names:
    • Jakavi®
  • Pharmaceutical Company:
    • NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
  • Condition/Indication: Myelofibrosis Graft versus host disease Polycythemia vera
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026